

Expertise to accelerate your lung cancer clinical trials

ppd



Evolving lung cancer treatment: Innovative solutions and clinical research advancements

According to the World Health Organization, lung cancer remains the most commonly occurring cancer worldwide, with approximately 2.5 million new cases annually, accounting for 12.4% of all cancer cases. This global health challenge demands urgent attention and innovative solutions through research and clinical trials.

The landscape of lung cancer treatment has evolved dramatically, with several new approaches to treatment that include advanced targeted therapies, novel immunotherapy combinations and precision medicine approaches.

In an era where the combination of speed and expertise is crucial for successful outcomes, the PPD™ clinical research business of Thermo Fisher Scientific has demonstrated substantial global experience in supporting studies ranging from first in human to global registrational Phase III precision medicine studies and adaptive study designs.

Leverage patient-centric technologies and end to end solutions that span all phases of lung cancer clinical trials and enable advance treatments for the patients who need them.

Over the past 10 years, more than 30 small to mid-sized biotechnology companies have turned to us to move forward their clinical trial development and expansion

Oncology drug developers need scalable and flexible solutions—we deliver. Emerging biotech firms or large multinational pharmaceutical corporations benefit from our flexible outsourced services, including pre-clinical research, clinical trial management and specialized manufacturing scaling, to more integrated solutions that encompass regulatory affairs, market access strategies and expanded manufacturing capabilities.

In the past five years, our expert lung cancer team has supported:

21,000+ patients

2,900+ global sites

60+ lung cancer trials (from early to late stage development)

We have managed and delivered several targeted treatments for lung cancer including:

- Oral MDM2 inhibitors
- Toll-like receptor 7 and 8 agonist
- Anti-cMET ADC
- SHP2 inhibitor
- DLL3 antibody-drug conjugate
- Anti-LILRB2 antibody
- Personalized neoantigen vaccine
- Anti-CTLA-4 antibody
- Tumor infiltrating lymphocytes
- PARP-1 inhibitor
- Bifunctional fusion protein
- EGFR/HER2 EXON inhibitor
- Anti VISTA antibody
- Anti PDL-1 antibody
- MK1/2 inhibitor
- RAS(ON) multi-selective inhibito

Unmatched lung cancer knowledge and experience

When it comes to developing treatments for lung cancer, it's imperative to shorten timelines and improve success rates. Our significant expertise in lung cancer research and global reach enables our clients to do just that — and our dedication to your study matches that of a niche CRO. Get the best of both worlds with services tailored to the unique needs of your study, sites and patients, while having access to industry leading experts prepared to implement innovative new approaches to design more efficient studies.

Key achievements

- Facilitated registration approval of PD-L1 inhibitor for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)
- Implemented an effective regulatory site activation and enrollment strategies for a complex platform design lung cancer protocol across North America, Europe and Asia-Pacific
- Initiated and surpassed enrollment targets for more than 50 sites across North America, Europe and the Middle Ease for a study on adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) in metastatic NSCLC

Over the past five years, our complete end-to-end solutions have supported more than 700 oncology studies. From recruitment to companion diagnostic development, submission applications to commercial launch, our broad capabilities support your needs.

Easing enrollment and increasing retention with patient-centric services

Lung cancer clinical trials can be burdensome for patients and their caregivers. To make it easier for patients to participate in trials, we offer a host of supportive concierge services that reduce burden for both sites and patients.

Telemedicine, Mobile Units and Home Healthcare Services	Digital and Decentralized Protocols
Transportation Coordination and Verification	eCOA/ePRO
Flexible Reimbursement Options	Wearables and Mobile Pages

The advantages of decentralizing clinical studies includes:

- Reduced recruitment timelines
- Improved patient retention
- Increased patient readiness
- Enhanced patient diversity

Through strategic preferred partnerships and expanded vendor capabilities, we can produce timely **and high-quality data** for our clients while saving patients time and cost. Our patient-centric approach has led to over **90% patient retention** over five years for a recent long-term follow-up trial.

Extensive expertise in the procurement and provision of comparator or standard of care treatments for lung cancer patients, in accordance with regulatory or site-specific requirements

Precision oncology for lung cancer

Biomarkers play a critical role in lung cancer trials, particularly in improving diagnosis, predicting prognosis, monitoring treatment response and personalizing therapy. Despite these advancements, there is significant room for improvement.

A large real-world study estimates that **497 out of every 1,000** newly diagnosed advanced NSCLC patients—nearly **50%**—are lost before even getting biomarker results back. These losses occur due to issues like unavailable or inadequate tissue samples, delays or not having the test ordered at all.

Thermo Fisher Scientific's Ion Torrent™ Genexus™ System* offers innovative next-generation sequencing (NGS) solutions for precision oncology. Oncomine™ Solutions offers a comprehensive portfolio of NGS assays that enable rapid genomic profiling for solid tumors and hematological malignancies. Our technology and global network of laboratories offer you tools to achieve faster patient recruitment, access diverse patient populations, and overcome sample availability challenges, effectively positioning you to meet key milestones faster.

As recent as 2022, study shows that ~50%of NSCLC patients are lost to precision oncology due to factors associated with biomarker testing.[1]

Efficient, on-site NGS testing reduces delays and risks associated with send-out testing, creating the ability to run more efficient trial timelines. Our global reach and proven history in supporting drug submissions and approvals empower our teams with the knowledge needed to lead in NGS innovation within precision oncology.

Kumar V., et al. Real-World Attrition of Patients With Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer Before Receipt of Therapy: Results From the US MYLUNG Consortium. JCO Precision Oncology. 2022;6:e2200065.

Oncomine Dx Express Test

The Thermo Fisher Ion Torrent™ Oncomine™ Dx Express Test provides genomic profiling for multiple solid tumors in as little as 24 hours using low sample input requirements including tissue and liquid biopsy expand samples.

Leverage our global regulatory experience and extensive network of more than 1,300 laboratories worldwide supported by dedicated in-country teams to accelerate development programs, expand access, and facilitate implementation from clinical trials to CDx development and commercialization.

We offer a wide range of solutions across the phases of oncology development. With experience across a range of cancer therapies, we support biomarker testing, companion diagnostics (CDx) development, clinical trial development and management, regulatory review, market access, and commercial strategy, helping accelerate the path to patients accessing therapies.

Our solutions provide global scalability, deep clinical experience, and seamless operational execution. Our end-to-end support ensures efficiency and success across the stages of your drug development journey.

Thermo Fisher Oncomine – Supporting trials across regions with a global network of testing sites